Key result
The HYVET 2 study protocol outlines a feasibility randomized controlled trial to evaluate the recruitment, adherence, and safety of treating white coat hypertension in 100 patients aged 75 years and older.
Why the study?
Definitive evidence supporting the treatment of white coat hypertension in the very elderly is currently not available.
Does treatment with indapamide and perindopril improve outcomes in very elderly patients (≥75 years) with white coat hypertension?
Does treatment with indapamide and perindopril improve outcomes in very elderly patients (≥75 years) with white coat hypertension?
This study protocol outlines a feasibility trial to determine if a full-scale RCT can be conducted to assess the clinical benefit of treating white coat hypertension in patients aged 75 years and older.
Should not yet change practice for white coat hypertension in elderly; feasibility protocol leaves open whether definitive RCT is viable.
The results of HYpertension in the Very Elderly Trial (HYVET) were crucial in providing evidence of benefit of the treatment of hypertension in those 80 years or older. Following a subsequent sub study analysis of the HYVET data there is a suggestion that 50% of patients in the main study had White Coat Hypertension (WCH), defined as clinic BP readings >140/90 mmHg and ambulatory BP readings <135/85 mmHg. Currently, definitive evidence in support of treatment for such individuals is not available. HYVET 2 has been designed in order to assess the feasibility of conducting a randomized controlled trial which might determine whether the treatment of WCH in the very elderly is clinically beneficial. One hundred participants aged ≥75 years diagnosed with WCH will be recruited from General Practices (GPs) in UK. Randomization will be 1:1 to a treatment arm (indapamide and perindopril) and control arm (no treatment) and follow up will be for 52 weeks. HYVET 2 will report on feasibility outcomes including participant recruitment, adherence and withdrawal rates, willingness of GPs to recruit and randomize patients and the frequency of a composite of cardiovascular events. Simple descriptive statistics will be presented.
No takes yet. Share an insight, caveat, or question.
Okorie et al. (2019) studied White Coat Hypertension (n=100). Indapamide MR and Perindopril Erbumine vs. No treatment was evaluated on Feasibility outcomes including participant recruitment, adherence, withdrawal rates, and willingness of GPs to recruit and randomize patients. The HYVET 2 study protocol outlines a feasibility randomized controlled trial to evaluate the recruitment, adherence, and safety of treating white coat hypertension in 100 patients aged 75 years and older.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: